The company said it will substantially eliminate the sales infrastructure related to Aduhelm, which is intended to provide savings of $1 billion annually when combined with other cost reductions.
Biogen CEO Michel Vounatsos will step down as the company continues to cut about $1 billion in costs annually, Biogen said Tuesday, after Medicare limited coverage for its Alzheimer’s drug, Aduhelm, to patients in clinical trials last month. The Food and Drug Administration approved Aduhelm for use in patients with mild cognitive impairment due to Alzheimer’s disease in June, but weeks later two congressional committees opened investigations into the FDA’s approval process for the drug.
